Bausch + Lomb vs Immunovant

Bausch + Lomb (BLCO), health care, and Immunovant (IMVT), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Bausch + Lomb is worth $7.4B on the stock market and Immunovant $6.9B: Bausch + Lomb is valued at 8% more. Over the past year Bausch + Lomb's share price has moved +38.3% and Immunovant's +40.5%.

Key facts

Bausch + Lomb market value
$7.4B
Immunovant market value
$6.9B
Bausch + Lomb revenue
$5.1BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Bausch + Lomb vs Immunovant: every measure side by side
Measure Bausch + Lomb Immunovant
SectorHealth CareHealth Care
Country Canada United States
Fiscal year ends2025-12-312026-03-31
Size
Market cap$7.4Bhigher$6.9Blower
Revenue$5.1B—
Earnings-$360Mhigher-$505.6Mlower
Employees13,000higher315lower
Total assets$14Bhigher$957Mlower
Valuation
P/E——
P/S1.5—
P/B—10.5
Dividend yield—0.00%
Profitability
Operating margin2.22%—
Balance sheet
Net assets$6.4Bhigher$852.6Mlower
Total liabilities$7.5Bhigher$104.4Mlower
Total debt$5B—
Cash on hand$383Mlower$902.1Mhigher
Price change
Today-0.24%lower-0.21%higher
1 year+38.3%lower+40.5%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Bausch + Lomb only (4)

Percentages are each holding's share of that investor's reported portfolio. Who owns BLCO · Who owns IMVT

Further comparisons

Learn

Questions and answers

Which is bigger, Bausch + Lomb or Immunovant?

By market value, Bausch + Lomb is the larger: $7.4B against $6.9B for Immunovant.

Which superinvestors own both Bausch + Lomb and Immunovant?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold Bausch + Lomb and 3 hold Immunovant.

Cite this page

Funkfolio, “Bausch + Lomb vs Immunovant”, data as of 18 November 2026. https://funkfolio.com/compare/blco-vs-imvt

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.